OBJECTIVE: Invasive pneumococcal disease is a major cause of preventable morbidity and mortality in the United States, particularly among the elderly (>65 years). There are large racial disparities in pneumococcal vaccination rates in this population. Here, we estimate the cost-effectiveness of a hypothetical national vaccination intervention program designed to eliminate racial disparities in pneumococcal vaccination in the elderly. METHODS: In an exploratory analysis, a Markov decision-analysis model was developed, taking a societal perspective and assuming a 1-year cycle length, 10-year vaccination program duration, and lifetime time horizon. In the base-case analysis, it was conservatively assumed that vaccination program promotion costs were $10 per targeted minority elder per year, regardless of prior vaccination status and resulted in the elderly African American and Hispanic pneumococcal vaccination rate matching the elderly Caucasian vaccination rate (65%) in year 10 of the program. RESULTS: The incremental cost-effectiveness of the vaccination program relative to no program was $45,161 per quality-adjusted life-year gained in the base-case analysis. In probabilistic sensitivity analyses, the likelihood of the vaccination program being cost-effective at willingness-to-pay thresholds of $50,000 and $100,000 per quality-adjusted life-year gained was 64% and 100%, respectively. CONCLUSIONS: In a conservative analysis biased against the vaccination program, a national vaccination intervention program to ameliorate racial disparities in pneumococcal vaccination would be cost-effective.
OBJECTIVE:Invasive pneumococcal disease is a major cause of preventable morbidity and mortality in the United States, particularly among the elderly (>65 years). There are large racial disparities in pneumococcal vaccination rates in this population. Here, we estimate the cost-effectiveness of a hypothetical national vaccination intervention program designed to eliminate racial disparities in pneumococcal vaccination in the elderly. METHODS: In an exploratory analysis, a Markov decision-analysis model was developed, taking a societal perspective and assuming a 1-year cycle length, 10-year vaccination program duration, and lifetime time horizon. In the base-case analysis, it was conservatively assumed that vaccination program promotion costs were $10 per targeted minority elder per year, regardless of prior vaccination status and resulted in the elderly African American and Hispanic pneumococcal vaccination rate matching the elderly Caucasian vaccination rate (65%) in year 10 of the program. RESULTS: The incremental cost-effectiveness of the vaccination program relative to no program was $45,161 per quality-adjusted life-year gained in the base-case analysis. In probabilistic sensitivity analyses, the likelihood of the vaccination program being cost-effective at willingness-to-pay thresholds of $50,000 and $100,000 per quality-adjusted life-year gained was 64% and 100%, respectively. CONCLUSIONS: In a conservative analysis biased against the vaccination program, a national vaccination intervention program to ameliorate racial disparities in pneumococcal vaccination would be cost-effective.
Authors: E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245
Authors: L A Jackson; P Benson; V P Sneller; J C Butler; R S Thompson; R T Chen; L S Lewis; G Carlone; F DeStefano; P Holder; T Lezhava; W W Williams Journal: JAMA Date: 1999-01-20 Impact factor: 56.272
Authors: Jane E Sisk; William Whang; Jay C Butler; Vishnu-Priya Sneller; Cynthia G Whitney Journal: Ann Intern Med Date: 2003-06-17 Impact factor: 25.391
Authors: Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Kenneth J Smith Journal: BMC Public Health Date: 2014-07-15 Impact factor: 3.295
Authors: Elizabeth T Cafiero-Fonseca; Andrew Stawasz; Sydney T Johnson; Reiko Sato; David E Bloom Journal: PLoS One Date: 2017-10-31 Impact factor: 3.240
Authors: Angela R Wateska; Mary Patricia Nowalk; Richard K Zimmerman; Kenneth J Smith; Chyongchiou J Lin Journal: BMC Infect Dis Date: 2018-01-25 Impact factor: 3.090